|
2011 Journal Article Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyPavel, Marianne E., Hainsworth, John D., Baudin, Eric, Peeters, Marc, Hörsch, Dieter, Winkler, Robert E., Klimovsky, Judith, Lebwohl, David, Jehl, Valentine, Wolin, Edward M., Öberg, Kjell, Van Cutsem, Eric, Yao, James C., RADIANT-2 Study Group and Wyld, D. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. The Lancet, 378 (9808), 2005-2012. doi: 10.1016/S0140-6736(11)61742-X |
|
2011 Journal Article Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot studyNewton, Melissa J ., Hayes, Sandi C., Janda, Monika, Webb, Penelope M., Obermair, Andreas, Eakin, Elizabeth G., Wyld, David, Gordon, Louisa G. and Beesley, Vanessa L. (2011). Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study. BMC Cancer, 11 (1) 389, 389-1-389-9. doi: 10.1186/1471-2407-11-389 |
|
2011 Journal Article Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancerRegan, Meredith M, Price, Karen N, Giobbie-Hurder, Anita, Thürlimann, Beat, Gelber, Richard D, International Breast Cancer Study Group and BIG 1-98 Collaborative Group, Colosimo, M., Cheuk, R., Kenny, L., McCarthy, N. and Wyld, D. (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast cancer research : BCR, 13 (3) 209, 209. doi: 10.1186/bcr2837 |
|
2011 Journal Article Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinomaObermair, Andreas, Mileshkin, Linda, Bolz, Katharina, Kondalsamy-Chennakesavan, Srinivas, Cheuk, Robyn, Vasey, Paul, Wyld, David, Goh, Jeffrey, Nicklin, James L., Perrin, Lewis C., Sykes, Peter and Janda, Monika (2011). Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. Gynecologic Oncology, 120 (2), 179-184. doi: 10.1016/j.ygyno.2010.10.039 |
|
2011 Conference Publication Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective studyBurge, M., Houston, K. E., Francesconi, A., O'Rourke, N., Lee, J., Macfarlane, D., Wyld, D., Hopkins, G., Finch, R. and Nathanson, L. (2011). Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011. Elsevier: Oxford, United Kingdom. |
|
2010 Journal Article Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patientsBeesley, Vanessa L., Clavarino, Alexandra M., Webb, Penelope M., Wyld, David K., Francesconi, Alessandra B., Horwood, Keith R., Doecke, James D., Loos, Colleen A. and Green, Adele C. (2010). Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Supportive Care in Cancer, 18 (8), 943-949. doi: 10.1007/s00520-009-0734-z |
|
2010 Journal Article Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agentLickliter, J. D., Francesconi, A. B., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Milne, R., McCarron, J., Yeadon, T., Wilks, A., Cubitt, A., Wyld, D. K. and Vasey, P. A. (2010). Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 103 (5), 597-606. doi: 10.1038/sj.bjc.6605841 |
|
2010 Journal Article Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 yearsGordon, Louisa G., Scuffham, Paul A., Beesley, Vanessa L., Green, Adele C., DeFazio, Anna, Wyld, David K., Clavarino, Alexandra M., Australian Ovarian Cancer Study Group and Webb, Penelope M. (2010). Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 years. International Journal of Gynecological Cancer, 20 (5), 757-765. doi: 10.1111/IGC.0b013e3181dbd13f |
|
2010 Journal Article Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX studyTebbutt, Niall C., Wilson, Kate, Gebski, Val J., Cummins, Michelle M., Zannino, Diana, Van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P., Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Price, Tim, Simes, John, Coates, Alan, O'Connell, Diane, Brown, Chris, Hague, Wendy, France, Alyson, Hicks, Sian, James, Rebecca, Masson, Ruby, O'Connell, Rachel ... Gebbie, Chantal (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. Journal of Clinical Oncology, 28 (19), 3191-3198. doi: 10.1200/JCO.2009.27.7723 |
|
2010 Journal Article Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiformeFrancesconi, Alessandra B., Dupre, Simon, Matos, Marco, Martin, David, Hughes, Brett G., Wyld, David K. and Lickliter, Jason D. (2010). Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience, 17 (8), 970-974. doi: 10.1016/j.jocn.2009.12.009 |
|
2009 Journal Article Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancersHerbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel and Scott, Andrew M. (2009). Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clinical Cancer Research, 15 (21), 6709-6715. doi: 10.1158/1078-0432.CCR-09-0536 |
|
2009 Journal Article Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 TrialAu, Heather-Jane, Karapetis, Christos S., O'Callaghan, Chris J., Tu, Dongsheng, Moore, Malcolm J., Zalcberg, John R., Kennecke, Hagen, Shapiro, Jeremy D., Koski, Sheryl, Pavlakis, Nick, Charpentier, Danielle, Wyld, David, Jefford, Michael, Knight, Gregory J., Magoski, Nadine M., Brundage, Michael D. and Jonker, Derek J. (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27 (11), 1822-1828. doi: 10.1200/JCO.2008.19.6048 |
|
2009 Journal Article Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosisFrancesconi, Alessandra Bastian, Matos, Marco, Lee, Joseph C., Wyld, David K., Clouston, Andrew D. and Macfarlane, David (2009). Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. Annals of Nuclear Medicine, 23 (5), 497-499. doi: 10.1007/s12149-009-0252-6 |
|
2008 Conference Publication Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancerLickliter, J., Francesconi, A., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Wilks, A., Wyld, D. and Vasey, P. (2008). Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer. 2008 ASCO Annual Meeting, Chicago, IL, U.S.A., 30 May - 3 June, 2008. Alexandria, VA. U.S.A.: American Society of Clinical Oncology. |
|
2007 Journal Article Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trialStockler, M. R., O'Connell, R., Nowak, A. K., Goldstein, D., Turner, J., Wilcken, N. R. C., Wyld, D., Abdi, E., Glasgow, A., Beale, P. J., Jefford, M., Dhillon, H., Heritier, S., Carter, C., Hickie, I. B. and Simes, R. J. (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8 (7), 603-612. doi: 10.1016/S1470-2045(07)70148-1 |
|
2007 Journal Article A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanomaKefford, Richard, Beith, Jane McNeil, Van Hazel, Guy Arthur, Millward, Michael, Trotter, James Marshall, Wyld, David Keith, Kusic, Rada, Shreeniwas, Revati, Morganti, Adele, Ballmer, Andrea, Segal, Eleonor, Nayler, Oliver and Clozel, Martine (2007). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Investigational New Drugs, 25 (3), 247-252. doi: 10.1007/s10637-006-9014-7 |
|
2007 Journal Article Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancerFriedlander, M, Buck, M, Wyld, D, Findlay, M, Fitzharris, B, De Souza, P, Davies, T, Kalimi, G, Allan, S, Perez, D and Harnett, P (2007). Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer, 17 (2), 350-358. doi: 10.1111/j.1525-1438.2007.00795.x |
|
2006 Journal Article Metastatic paraganglioma with extensive bone marrow involvementMorris, Kirk L., Macfarlane, David, Wyld, David and Kennedy, Glen A. (2006). Metastatic paraganglioma with extensive bone marrow involvement. Asia-Pacific Journal of Clinical Oncology, 2 (4), 193-194. doi: 10.1111/j.1743-7563.2006.00068.x |
|
2005 Conference Publication Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.Sabesan, SS, Wyld, D, Herath, N and Boyd, A (2005). Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.. 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando Fl, May 13-17, 2005. AMER SOC CLINICAL ONCOLOGY. |
|
2005 Conference Publication A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanomaKefford, R, Beith, J, Van Hazel, GA, Millward, M, Trotter, J, Wyld, D, Kusic, R, Coward, J, Shreeniwas, R and Morganti, A (2005). A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanoma. ESMO Scientific and Educational Conference (ESEC), Budapest Hungary, Jun 02-05, 2005. OXFORD: OXFORD UNIV PRESS. |
